Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy

被引：19
|
作者：
Hopkins, Jessica L. [1 ]
Zou, Lee [1 ,2 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Charlestown, MA 02129 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
来源：
CANCER CELL | 2019年 / 36卷 / 05期
关键词：
D O I：
10.1016/j.ccell.2019.10.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this issue of Cancer Cell, Quereda and colleagues report that a newly developed specific inhibitor of CDK12/13, SR-4835, sensitizes triple-negative breast cancer cells to PARP inhibitors and DNA-damaging chemotherapeutics by reducing expression of the genes in the DNA damage response pathway.
引用
收藏
页码：461 / 463
页数：4
相关论文
共 50 条
  • [21] Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
    Mayer, Erica L.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3369 - +
  • [22] Platinum chemotherapy for early triple-negative breast cancer
    Mason, Sofia RE.
    Willson, Melina L.
    Egger, Sam J.
    Beith, Jane
    Dear, Rachel F.
    Goodwin, Annabel
    BREAST, 2024, 75
  • [23] Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer
    Elizabeth, Melendez Solano
    Cristina, Stevens Barron Jazmin
    Christian, Chapa Gonzalez
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (04) : 431 - 439
  • [24] Identification of novel CDK12 inhibitors that synergize with PARP inhibition through induction of 'BRCAness' phenotype
    Ainscow, Edward K.
    Bahl, Ashwani
    Thompson, Stuart
    Flatt, Luke
    Crepin, Damien
    Stevenson, Brett
    CANCER RESEARCH, 2020, 80 (16)
  • [25] Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer
    Locatelli, Marzia A.
    Curigliano, Giuseppe
    Eniu, Alexandru
    BREAST CARE, 2017, 12 (03) : 152 - 158
  • [26] BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
    Kosaka, Yoshimasa
    Yamamoto, Yutaka
    Tanino, Hirokazu
    Nishimiya, Hiroshi
    Yamamoto-Ibusuki, Mutsuko
    Hirota, Yuko
    Iwase, Hirotaka
    Nakamura, Seigo
    Akashi-Tanaka, Sadako
    DIAGNOSTICS, 2020, 10 (02)
  • [27] BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
    Mori, Hitomi
    Kubo, Makoto
    Nishimura, Reiki
    Osako, Tomofumi
    Arima, Nobuyuki
    Okumura, Yasuhiro
    Okido, Masayuki
    Yamada, Mai
    Kai, Masaya
    Kishimoto, Junji
    Miyazaki, Tetsuyuki
    Oda, Yoshinao
    Otsuka, Takao
    Nakamura, Masafumi
    PLOS ONE, 2016, 11 (12):
  • [28] A selective Cdk12/13 non-covalent inhibitor with potent anti-breast cancer activity
    Quereda, V.
    Bayle, S.
    Francesca, V.
    Andrii, M.
    William, R.
    Derek, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takashima, Tsutomu
    Morisaki, Tamami
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [30] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takahashi, Katsuyuki
    Takashima, Tsutomu
    Noda, Satoru
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
12345